OVID Relative Valuation
OVID's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OVID is overvalued; if below, it's undervalued.
Historical Valuation

No Data
Competitors Valuation Multiple
The average P/S ratio for OVID's competitors is 18.74, providing a benchmark for relative valuation. Ovid Therapeutics Inc Corp (OVID) exhibits a P/S ratio of 91.22, which is 386.83% above the industry average. Given its robust revenue growth of -12.16%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch

AAPL
Apple Inc
208.780
USD
-1.17%

TSLA
Tesla Inc
342.090
USD
-2.25%

MSFT
Microsoft Corp
458.870
USD
+1.01%

META
Meta Platforms Inc
640.430
USD
+0.01%

NVDA
NVIDIA Corp
135.570
USD
+0.13%

AVGO
Broadcom Inc
230.630
USD
+0.88%

AMZN
Amazon.com Inc
206.160
USD
+0.28%

ORCL
Oracle Corp
159.640
USD
-0.53%

WMT
Walmart Inc
98.120
USD
-0.12%

XOM
Exxon Mobil Corp
106.470
USD
-1.59%
FAQ

Is Ovid Therapeutics Inc (OVID) currently overvalued or undervalued?
Ovid Therapeutics Inc (OVID) is now in the Fair zone, suggesting that its current forward PS ratio of 91.22 is considered Fairly compared with the five-year average of 448.18. The fair price of Ovid Therapeutics Inc (OVID) is between 0.05 to 1.17 according to relative valuation methord.

What is Ovid Therapeutics Inc (OVID) fair value?

How does OVID's valuation metrics compare to the industry average?

What is the current P/B ratio for Ovid Therapeutics Inc (OVID) as of May 20 2025?

What is the current FCF Yield for Ovid Therapeutics Inc (OVID) as of May 20 2025?

What is the current Forward P/E ratio for Ovid Therapeutics Inc (OVID) as of May 20 2025?
